XENE stock news · Xenon Pharmaceuticals Inc.
Get alerts for XENE
Follow Xenon Pharmaceuticals Inc. (XENE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for XENEXenon Pharmaceuticals gave stock options and shares to nine new employees starting October 29, 2026.
NeutralXenon granted stock awards to 9 new employees. The awards could add shares over time, but the report gives no sign of a change in the company's business outlook.
Xenon Pharmaceuticals shares details from their earnings call for the second quarter of 2026.
Good for XENEXenon ended Q2 with $1.2 billion in cash and plans to seek FDA approval for azetukalner later this quarter. This supports a stronger outlook, though approval is not assured.
On Friday, 12 health care stocks changed a lot in price, with IM Cannabis jumping 246%.
Bad for XENEXenon Pharmaceuticals shares declined 30.2% to $40.01. The drop reduces the market value of its shares and signals negative investor reaction today.
U.S. stocks had mixed results as industrial production stayed the same in August.
Bad for XENEXenon Pharmaceuticals paused enrollment of new patients in psychiatry studies and saw price-target cuts, and its shares fell to $42.32, which worsens near-term program prospects.
A Netflix expert is now less positive; check out the five biggest rating cuts for Friday.
Bad for XENEXenon Pharmaceuticals was cut from Buy to Hold and its price target was slashed to $46, signaling weaker analyst confidence in the biotech's near prospects.
Xenon Pharmaceuticals, Steel Dynamics, Nucor, and other major stocks dropped in early trading on Friday.
Bad for XENEXenon paused enrollment in psychiatry studies after neuropsychiatric events; I read this as bearish for Xenon.
On Thursday evening, 12 health care stocks changed a lot in price.
NeutralXenon Pharmaceuticals shares fell 23.7% to $43.75 after hours, but the article only reports the price drop and no regulatory or company disclosures, so it does not change the company's outlook.